Stage III Renal Pelvis Cancer AJCC v8

10 clinical trials · Condition

Record	Firm	Date
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study (NCT05092958)	National Cancer Institute (NCI)	2022-06-03
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma (NCT04940299)	M.D. Anderson Cancer Center	2021-09-23
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma (NCT03513952)	National Cancer Institute (NCI)	2019-06-05
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer (NCT03617913)	Mayo Clinic	2018-09-19
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer (NCT03237780)	National Cancer Institute (NCI)	2018-07-20
Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors (NCT02496208)	National Cancer Institute (NCI)	2015-07-22
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer (NCT00749892)	M.D. Anderson Cancer Center	2008-06-10

Every clearance here is in the API, with alerts when new ones post.